Larvol Delta - ASCO-GU-2025-CONVERGE01-Dosimetry-Randomized-Dose-Optimization-Dose-Escalation-and-Efcacy-of-Ac225-Rosopatamab-Tetraxetan-in-Participants-with-PSMAPositive-CRPC

Ac-225 rosopatamab tetraxetan (CONV01-α) - Dominari Holdings

https://www.urotoday.com/conference-highlights/asco-gu-2025/asco-gu-2025-prostate-cancer/158312-asco-gu-2025-converge-01-dosimetry-randomized-dose-optimization-dose-escalation-and-efficacy-of-ac-225-rosopatamab-tetraxetan-in-participants-with-psma-positive-crpc.html

Feb 16, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next